INKT MiNK Therapeutics, Inc.

Nasdaq minktherapeutics.com


$ 14.04 $ 0.19 (1.37 %)    

Friday, 31-Oct-2025 15:58:43 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 14.04
$ 14.05
$ 13.73 x 10
$ 14.62 x 50
$ 13.91 - $ 14.24
$ 4.56 - $ 76.00
28,660
na
63.5M
$ 2.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-24-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-18-2022 12-31-2021 10-K
16 11-29-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mink-therapeutics-announces-that-late-breaking-phase-1-data-for-its-allogeneic-inkt-cell-therapy-agent-797-will-be-presented-at-40th-annual-sitc-meeting-nov-79-2025

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural kille...

 hc-wainwright--co-upgrades-mink-therapeutics-to-buy-maintains-price-target-to-35

HC Wainwright & Co. analyst Emily Bodnar upgrades MiNK Therapeutics (NASDAQ:INKT) from Neutral to Buy and maintains the ...

 mink-therapeutics-q2-eps-106-misses-046-estimate

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $...

 hc-wainwright--co-downgrades-mink-therapeutics-to-neutral-maintains-price-target-to-35

HC Wainwright & Co. analyst Emily Bodnar downgrades MiNK Therapeutics (NASDAQ:INKT) from Buy to Neutral and maintains th...

 mink-therapeutics-highlights-inkt-cell-therapy-potential-in-peer-reviewed-article-titled-car-inkt-cells-redefining-the-frontiers-of-cellular-immunotherapy-underscoring-the-power-of-car-inkt-as-next-gen-solid-tumor-treatment

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural kille...

 william-blair-downgrades-mink-therapeutics-to-market-perform

William Blair analyst Matt Phipps downgrades MiNK Therapeutics (NASDAQ:INKT) from Outperform to Market Perform.

 why-is-nano-cap-mink-therapeutics-stock-gaining-over-400-on-friday

MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION